Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So:
The Royal Oldham Hospital in Oldham (near Manchester)
Stepping Hill Hospital in Stockport (near Manchester)
Royal Bolton Hospital in Bolton (near Manchester)
Royal Albert Edward Infirmary in Wigan (near Manchester)
Tameside General in Ashton-under-Lyne (near Bolton)
I haven't counted how many hospitals there are in that area, but it seems like a fairly good hit-rate.
Apologies - I might of mixed up the tests in my early morning excitement.
A senior moment - what I’m saying is - this shows great revenue potential 😃.
I think both REX and open offer will be over subscribed just like SCE did.
15p - 20p a share is very very cheap based on the national roll out revenues but I agree it's more than doable in 2024. It is why many shareholders are snapping up the REX, Open Offer and Placing shares at 1.5p, as once the NHS start buying GDR'S MT-RNR1 ID Kit nationally the revenue moving forwards is very attractive for Genedrive:
* £8.5 million from UK revenue per year
* £46.8 million from EU revenue per year
* £34 million from US revenue each year
* £13.8 million from the rest of the world revenue each year
Roll on July 10th.....
Good luck all GDR investors, Brighty
WOW NO WAY!!!!
The CEO is spending £10K on GDR shares from his £300,000.00 P.A. income.
🤣🤣🤣
Started: stephen11, Today 07:26
Last post: stephen11, Today 07:26
Let’s put this in context .
I’d call this a taster of what is to come.
If 5 new sites gives you an order of £100,000 think what revenue we could receive when this is rolled out nationwide? Remember, through the DEVOTE program and the work of are partners in Manchester University we are gathering data to support full NICE adoption.
And there’s more………..
The CYPC19 is also receiving full NICE accreditation in the UK on the 10th July 2024. That means full adoption in the UK - the NHS are obliged to use the test - it’s there own rules.
1.5p is starting to look like the bargain of the year 💰💰💰💰
GLA.
A happy 😃 Stephen11.
Started: Newbieinvest, 22 May 2024 12:56
Last post: molatovkid, Today 07:21
Not overly happy with this entire situation, but the placing is so heavily discounted that it offers a good opportunity to average down and hope they find a way forward. Applied for double my holding.
It went to £3 on Covid hype and about 50 million shares in circulation
50 million shares is now about a fiver
I looked in my account yesterday and saw the open offer. I know I've been saying all along that I'm voting no, but I've given it careful thought. When I think about it I dont really have much choice. If shareholders vote No and let it drag on, I can only see the SP tumbling more. I dont have a massive holding, so when I saw how much it would cost to buy up as many shares as I already have, it really was a no brainer. This would bring my average down to around 18p. With the fundamentals the company has, I can see this rising at some point to at least 15p if not more, and thats wih 550M shares on the market. So I've just bought all my holdings and a little more which will take my average down to 15p. It really is a no brainer. If you believe in the Company and the tests we currently have within the NHS, and the stroke test to come, if you really believe that we will start expanding on a large scale to the UK and the rest of the world, then it really is a no brainer. Expansion on that scale would bring the SP to well over a pound. We've been there before, in fact we've been up to £3 just a few years ago and we hadn't got as far as we have now with the tests. With the SP still above the 1.5p mark, your quids in already.
Tiger tiger, it’s not inside information and one broker even publicised at the start of this week the fact they had 7.5m shares on their books and that in the 1:1 offer they still had 1.6m shares left to be applied for!
Stocksaint, is it not a combined between the 2 for at least £6m so £5m for one and £1m for the other as long as we get the minimum ?????
Started: JoeyBloggs7, 23 May 2024 15:43
Last post: JoeyBloggs7, 23 May 2024 15:43
For all the badmass lot 🤣
Started: PimpMyReturns, 22 May 2024 11:33
Last post: Wdasse, 22 May 2024 17:53
Halifax deadline is Friday 24/05 and monies must be available by the 26/05
1pm 23rd according to Charles Stanley.
Guys anyone pls, when is the dead line for the C>Action share pledge ?
Consolidation, I hope not as the result is usually an effective drop in shares value.
Mr MYPIMPRETURNS,
"Somewhere between £0.007pence and £0.014 pence? Higher or lower ?"
Surely, GDR will announce a reevaluation of SP. I can't remember what they call the process to turn a share worth 0.01p the equivalent of a new share worth 100p. But that's what GDR will do.
Started: Glyn10, 22 May 2024 15:55
Last post: Glyn10, 22 May 2024 16:16
Yep not the best choice i've ever made but, as i s
Reading your previous 3 posts was depressing , you've seen this absolutely crash
I've opted to buy more at the 1.5p offer, if I get what I've applied for, will bring my average down to 79p.... yep I brought at a high price when everything looked like it could only go up! but, I still believe in Genedrive, they have some amazing products, just need to get them sold... fingers crossed for the future (non trader, just interested in this company and what they can hopefully do for the good of medicine)
Started: crober33, 22 May 2024 08:12
Last post: roger65, 22 May 2024 11:23
I’d say it’s nailed on. There is no way any ii would put £ms into GDR on a whim. And clearly there are some iis (my suspicion is one of them is RF) have decided to put several £m in at 1.5p
The crucial thing is what happens if retail don’t come up with the extra cash needed in order to get this up to the requisite £6m or so. Surely the BODs don’t just hand all the money offered in these various placings back. BOD cd not have been clearer in the placing RNS : cough up big time or else!
This will be the very last time GDR can get away with luring retail investors in unless it all comes off.
Big questions still remain about the near term future. What do these iis do if the sp doubles to 3p? Will they immediately dump? Could be a very short lived recovery with retail left holding the baby yet again whilst the iis walk off with their pockets full and a quick 100% profit.
GDR has never been such a risky punt as now imo
PALOH study video..https://x.com/ManchesterBRC/status/1793219060609536131
Is the expected news guaranteed ?
Happy either way.
There'll soon be half a billion new shares , it will get cheaper
To get in with expected news
Started: Trickymatters, 21 May 2024 17:54
Last post: GloriaMarket, 22 May 2024 09:25
"
On the evidence of GDR, guess where the share price is going!
"
That report is evidence that many people on this chat site have been lucky in life. It wasn't financial brains that earned them the money they have to invest in GDR!
Tricky, you won’t see a TR1 because RF never held on to their shares long enough to establish a holding large enough to warrant a TR1 in the first place.
Tricky not knowing what she’s going on about .. somethings never change
Yes the RF deal was bad and led to the slide in the SP. However, it was confirmed they hold no shares and GDR has now clearly decided against any further drawdowns so that's the end of it. Good riddance.
Hardman report:
From recent Hardman report:
Genedrive
As the old saying goes: “if it is difficult to understand, it is almost certainly detrimental
to shareholders”. Never has this been more true than in the case of Genedrive (and
more recently, Sareum). Although I accept that the board was probably in a difficult
position with a shareholder list of mostly retail investors, but desperate for cash, the
loan facility announced in March 2023 with Riverfort Global Opportunities PCC Ltd
(Riverfort) is extremely complex. After more than 35 years as an analyst, I consider
myself reasonably financially literate. However, I can honestly say that I have read
this agreement at least 10 times and I still do not fully understand it!
In summary, Riverfort made £5m available to the company. £2m was drawn down
immediately with the remaining £3m available for £0.3m monthly drawdown subject
to certain conditions being fulfilled. The loan capital is being repaid through the
issuance of new shares to Riverfort priced on a specific calculation (reference price)
and can be sold in the market, based on a series of conditions related to daily
volumes traded. On each drawdown, Riverfort also receives warrants equal to 40%
of the drawdown at the recalculated reference price, exercisable at 140% of this
reference price. The following table shows what has happened to date.
In my opinion, this deal is very bad for shareholders. To date, the issue of shares to
repay the loan capital represents dilution of 32.3%. The main reason for this is that
Riverfort is not a long-term shareholder, as evidenced by the fact that it sold down
its holding of 6.5m shares received in April to only 2.95m (-55%) by July. Even
though it has received more shares, its holding is not disclosed as being >3.0%
declarable threshold. Therefore, it is continually selling shares, which, in turn, causes
the share price to fall, making the next drawdown even more expensive.
Based on the current share price, Genedrive will need to issue an estimated18.25m
more shares and a further 8.0m warrants, which would provide the potential to raise
another £0.85m. dilution of 56% and in the
event that all the warrants are exercised, this would increase to 78%, but potentially
raise a further ca.£2.8m. However, given that most of the warrants are out of the
money, there is a high probability that the warrants will not be exercised.
Amazingly, Sareum announced a similar deal with the same investor in November.
On the evidence of GDR, guess where the share price is going!
The RNS gave me some reassurance on two fronts. Firstly, it was an attempt to buoy up the SP and keep up the interest which indicates that the placing is not a charade to disguise going private. Secondly, the RNS confirms the company's view that full recommendation is expected. Therefore, the company at least has not heard anything since to indicate that the final recommendation will be any different to the draft.
The market doesn’t trust Gilliam and the 3 amigos !
Great endorsements from both Profs Newman and Prof Bridgewater excellent work Genedrive team
Now there are mouth to feed so at best this could go up about 5p in 1 to 2 years. Don't. expect to make big bucks unless you are a new investor who was chooen (!) by the CEO's cronies. This is good as taking private.
Great news , timing seems perfect as we only have a few days left to action the nominate our purchase of the placing shares , which almost now will be over prescribed ...
One would be a fool not to take up the 1,5 p share option now ... this is not financial advise ...
RUA getting ready to explode ... you heard it here first ..
Started: David6576, 21 May 2024 11:50
Last post: Slacker246, 21 May 2024 17:23
Answer the question Cheeky will you take the company private??
I'll just assume all of america had a lay in today
Well I was expecting some positive RNS to land, to convince RI's in a timely manner over the line. this one is pretty mediocre but when one has a large salary to protect...i d be releasing an RNS about the fragrant smell of my fart frankly. Tiger you get the prize for buffoon of the week, saying it will multi bag to 20P + in weeks, followed by saying "nobody knows for sure" hhaha.. clown costume in post.
Hahaha what a clown, not heard wait for the americans to wake up for a while
Absolute nothing will happen in the afternoon the yanks can buy now if they want and they haven’t
Last post: Newuncle, 21 May 2024 13:39
Systemzero, very good advice there.
Tiger...bit of advise.. don,t take Doctor Death,s essay seriously...he,s a snake in the grass...
Roger, that’s what I keep wondering… why have they imposed a minimum amount or nothing policy? The only rationality in that for me is if they have a plan B organised that will also give them the minimum amount but just at worse terms (more dilution etc).
Roger thanks for your post and apologies for sounding optimistic ... I am also in the red as well by the way .. no one really know what will happen here , the partner in the USA, the NICE approval and then the placing .. it could go either way .. all these post here are all speculations and most a idiots spouting rubbish against each other .. which is no use to us .. lets please all endeavor to post like roger ..
Doctor Death .,back to his old tricks...he wants to buy in lower than 1.5p...so is scaremongering...with his long winded essay,s
Started: David6576, 21 May 2024 12:06
Last post: David6576, 21 May 2024 12:06
Long way to go.
Started: JAMESY1980, 21 May 2024 12:01
Last post: JAMESY1980, 21 May 2024 12:01
RNS is a good sign IMO. They want the funding to suceed. The whole thing isn't a charade to take private for peanuts which had crossed my mind.
Last post: mcleod, 21 May 2024 11:33
Someone is likely to acquire this company
NICE guidance is not optional - there is a massive focus on health inequalities and if someone in the 30% has an adverse event due to either under or over metabolism of clopidogrel then there will be a legal liability. So Trusts and providers will have to be using this test. Would expect very rapid uptake across the NHS
Started: stephen11, 21 May 2024 11:22
Last post: stephen11, 21 May 2024 11:22
This news will open up sales in the European market in early 2025.
In context, CE-IVD certification is a proof of compliance with current regulations and standards. It is required for commercialization in vitro diagnostics (IVD) devices in Europe.
And......i loved the nod to NICE being on track for the 10th July:
"The UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance, that the Genedrive® CYP2C19-ID test should be used as the point-of-care test of choice in the NHS before clopidogrel administration in the management of IS and TIA patients (https://www.nice.org.uk/guidance/indevelopment/gid-dg10054/documents). The draft guidance is expected to be finalised on 10 July 2024."
Great News!
GLA.
Stephen11
Started: David6576, 21 May 2024 11:15
Last post: Brighty1, 21 May 2024 11:20
Exactly & with over 77 million people globally having ischaemic strokes each year there is a huge gap in the market for GDR to exploit.
* The key point is GDR's CYP2C19 ID stroke Kit targets the most common type of stroke
* The UK Stroke Association estimate that there are 100,000 strokes each year in our country
* The EU market for CYP2C19 could be worth £93.5m each year to GDR according to recent guidance
* The UK market for CYP2C19 could be worth £8.5 m each year in revenues to GDR
These numbers are not to be sniffed at....
Good luck, Brighty
Big Pharma jV will follow now
The UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance, that the Genedrive® CYP2C19-ID test should be used as the point-of-care test of choice in the NHS before clopidogrel administration in the management of IS and TIA patients
That reads decent tbf
Where’s the money coming from to keep going ?
Massive achievement after a long wait and way overdone stock.
Last post: IrnHaggis, 21 May 2024 11:07
Nothing stopping this quickly of returning to 10p
Started: stephen11, 21 May 2024 11:05
Last post: stephen11, 21 May 2024 11:05
Key CYP2C19-ID test performance milestone achieved
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that a key milestone has been met in The Development and Validation of Technology for Time Critical Genomic Testing ("DEVOTE") programme for its CYP2C19-ID kit. The programme has now passed the patient numbers required for a subsequent submission for an in vitro diagnostics CE certification ("CE-IVD"), which is still anticipated in early 2025.
GLA.
Stephen11.
Started: JoeyBloggs7, 20 May 2024 18:11
Last post: james2k66, 21 May 2024 11:04
Speaking if hitting a milestone, milestone rns
They definitely stand a chance of doing it if they can raise the £6m. On the other hand, will always be significant chance of another raise, especially is £6m isn't really a lot of money, so little margin for error in the forecast. At the same time, if they hit some milestones, they might not so much difficulty raising more money from IIs anyway.
It’s stated in the 9 May RNS the forecast is positive EBITDA in first half 2026, it also details how they’ll get there in respect of sales and revenue from each product, subject to the expected caveats.
True Slacker, but why bother repeating the same tiresome post over and over again. There's lots of basket case companies on AIM anyway. To me the very fact that the REX platform exists is further proof that AIM is in trouble. It obviously difficult for firms like these to raise all the capital they need from IIs in the traditional way as before, through underwritten placings.
Stand back everyone.. what's left of Spackers brain is about to explode...
Started: bigAl67, 18 May 2024 08:51
Last post: Metatron, 20 May 2024 19:18
Gloria.. you appear to have been drinking.. I approve.. sometimes it's necessary in order to say what needs to be said.
Meanwhile.. Joey.. you make me LMAO.. once a cretin always a cretin LMAO
"Bigliar67- you said we where funded until 2025 without the need for a raise, you clearly lied again!"
No mr Carlos, mr bigal didnt lie, hes simply not very good at simple maths nor reading RNSes and then calls his opinions " the Truth" with a capital T.
Excuses typos!
"Clearly another one of the Troll 'Group' Team."
Difficult to pin point theexactsp when mr bigal started making accussations like this, but the spwas probably well over 50p at the time. Its now 1.6p. Which shows that the rapers such as mr bigal are the trolls and not the people who mrbigal accusrs of being a troll. I find it disturbingly disrrspectful tbh. Makes me think of the senior management at Post Office limited denying the problems with their horizon software.
"- But the Truth does not fit with Your Agenda."
Correction mr bigal,
"- But my Opinion does not fit with Your Opinion."
Corrected. Do carry on.
Last post: Systemzero, 20 May 2024 12:08
Yes... I believe that's the case
Guys please some one be kind enough to answer me , if the raise fails will i get a refund on the placing shares i buy ?
Started: Fredd1eboy, 19 May 2024 18:13
Last post: Bankruptstock, 20 May 2024 11:59
They have no money left for research all their eggs are now in NICE approval in July
Is Gene drive heading up research into genetically modifying mosquitos to assist eradication of malaria by partnering research and testing with Imperial College in London?
Started: Bankruptstock, 20 May 2024 11:57
Last post: Bankruptstock, 20 May 2024 11:57
Which existing holder will want to take up the offer price of 1.5p when this can be bought cheaper on the open market soon. James Cheek has turned out to be worse than Budd and that takes some doing.
Started: stephen11, 19 May 2024 08:58
Last post: MisterPositive, 20 May 2024 09:40
I have Doubled my Holding here adding under 2p and taking up my full 1 for 1 entitlement also.
Been extremely busy lately so not had time to post but browse through the comments here from time to time.
Despite placing coming at 1.5p instead of 3p...future is looking very bright here. Even with 400m extra shares to be added to current 143m shares....total shares in issue will still be low 543m which is nothing compared to some other companies with over 20 Billion shares about.
Once £6m is in the bank...this should move higher quite rapidly this summer ahead of 10 July NICE recommendation publication date. So just add or sit tight. This can get to well over £100m MCap pretty quickly as Sales start to increase substantially over coming 6-12 months. We got a target market of £300m in Annual revenues.
You will look back next year and say why the he11 did I not get more shares in 2024 at all time lows.
Good Luck all & the very best for the future.
MP
MIKODX - not sure what you are proposing, but GDR have stated they only had 7 weeks of cash runway. The SP before they announced the placing was 2.8p. How would you have got to a 3p placing for twice the MCap?
It is 400m new shares, not 400k and also worth pointing out that that is a minimum. Taking all of the headwinds into account, I'm taking up my full placing allocation and also buying below 2p as I think it represents a good bet from here. I believe the SP will stay over 1.75p, the placing will be successfull and the SP will recover to 2.5p without significant news, i.e. and MCap in the £12-13m ballpark. Ive been wrong here before but that is where my money is regardless. Good luck.
With AIHL in the latter stages of final approval from NICE, and with CYP2C19 looking highly likely to be approved in July, a Placing of 3p would have been acceptable to shareholders, I'm sure they would have backed the company. It would have meant only 200,000 share dilution instead of the now 400,000. The SP would have most likely held at 3p and the company would have been in a great position to move up from there.
JAMESY1980 - If that's your logic, then there's no point me explaining. With only six posts, you wouldn't understand.
MIKODX - A very naive suggestion from someone with 3k posts. Can you think of any example of a company raising more than twice it's MCap at a minimal discount? Crazy...
I believe that the placing is as well constructed as it could be taking the preceding position into account. An unsuccessful placing of any form would be a very fragile place to be for incumbent investors.
Started: Ldakmail, 20 May 2024 08:24
Last post: Ldakmail, 20 May 2024 08:24
X-O showed an initial allocation of 7.5m (ish) shares on OO release and currently show 1.625m available after the 1:1 takeup. That's 78.3%.
Any extras requested will come out of the 1.625m left I imagine.